-
EP1501861
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1501861
| EP1501861 - TARGETING PROTEINS TO DELIVER THERAPEUTIC OR DIAGNOSTIC REAGENTS [Right-click to bookmark this link] | Status | The application has been refused Status updated on 18.06.2010 Database last updated on 15.06.2024 | Most recent event Tooltip | 18.06.2010 | Refusal of application | published on 21.07.2010 [2010/29] | Applicant(s) | For all designated states BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 201 West Seventh Street Austin, TX 78701 / US | [N/P] |
| Former [2005/05] | For all designated states BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM 201 West Seventh Street Austin, TX 78701 / US | Inventor(s) | 01 /
HUNG, Mien-Chie 5762 Birdwood Road Houston, TX 77096 / US | 02 /
LAN, Keng-Li 7447 Cambridge Apt. 46 Houston, TX 77054 / US | 03 /
OU-YANG, Fu 7777 Greenbriar Drive Houston, TX 77030 / US | 04 /
LIU, Jaw-Ching 7777 Greenbriar Drive Houston, TX 77030 / US | 05 /
LAN, Keng-Hsin 6F-1, No. 3. Lane 151 Sec. Z, Fu-Hsing S. Rd Taipei Taiwan 106 / TW | [2005/05] | Representative(s) | SONN Patentanwälte GmbH & Co KG Riemergasse 14 1010 Wien / AT | [N/P] |
| Former [2005/05] | Sonn & Partner Patentanwälte Riemergasse 14 1010 Wien / AT | Application number, filing date | 03733952.0 | 06.05.2003 | [2005/05] | WO2003US14243 | Priority number, date | US20020380063P | 06.05.2002 Original published format: US 380063 P | [2005/05] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO03093303 | Date: | 13.11.2003 | Language: | EN | [2003/46] | Type: | A1 Application with search report | No.: | EP1501861 | Date: | 02.02.2005 | Language: | EN | The application published by WIPO in one of the EPO official languages on 13.11.2003 takes the place of the publication of the European patent application. | [2005/05] | Search report(s) | International search report - published on: | US | 13.11.2003 | (Supplementary) European search report - dispatched on: | EP | 23.05.2007 | Classification | IPC: | C07K19/00, A61K38/00, C12N15/62, C07K14/78 | [2007/24] | CPC: |
C07K14/78 (EP,US);
A61K47/66 (EP,US);
A61P35/00 (EP);
A61P43/00 (EP);
A61P9/00 (EP);
B82Y5/00 (EP,US);
C07K14/5434 (EP,US);
C12N9/78 (EP,US);
A61K38/00 (EP,US);
|
| Former IPC [2005/05] | C07K1/00 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR [2005/05] | Extension states | AL | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | Title | German: | GEZIELT BINDENDE PROTEINE ZUR VERABREICHUNG THERAPEUTISCHER ODER DIAGNOSTISCHER REAGENTIEN | [2005/05] | English: | TARGETING PROTEINS TO DELIVER THERAPEUTIC OR DIAGNOSTIC REAGENTS | [2005/05] | French: | CIBLAGE DE PROTEINES POUR L'APPORT DE REACTIFS THERAPEUTIQUES OU DE DIAGNOSTIC | [2005/05] | Entry into regional phase | 26.11.2004 | National basic fee paid | 26.11.2004 | Search fee paid | 26.11.2004 | Designation fee(s) paid | 26.11.2004 | Examination fee paid | Examination procedure | 05.12.2003 | Request for preliminary examination filed International Preliminary Examining Authority: US | 26.11.2004 | Amendment by applicant (claims and/or description) | 26.11.2004 | Examination requested [2005/05] | 27.09.2007 | Despatch of a communication from the examining division (Time limit: M06) | 04.04.2008 | Reply to a communication from the examining division | 09.10.2008 | Despatch of a communication from the examining division (Time limit: M04) | 09.02.2009 | Reply to a communication from the examining division | 02.03.2010 | Cancellation of oral proceeding that was planned for 19.03.2010 | 05.03.2010 | Despatch of communication that the application is refused, reason: substantive examination [2010/29] | 15.03.2010 | Application refused, date of legal effect [2010/29] | 19.03.2010 | Date of oral proceedings (cancelled) | Fees paid | Renewal fee | 27.05.2005 | Renewal fee patent year 03 | 10.05.2006 | Renewal fee patent year 04 | 30.05.2007 | Renewal fee patent year 05 | 28.03.2008 | Renewal fee patent year 06 | 12.05.2009 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [DX]WO9916889 (SEARLE & CO [US], et al) [DX] 1-3,6,7,10-12,16-19,23,24 * claim - *; | [X]WO0011033 (LEXINGEN PHARMACEUTICALS CORP [US]) [X] 1-4,6,7 * claim - *; | [X]WO0105826 (GPC BIOTECH INC [US]) [X] 1-4,6,7,10-12,16-19,23,24 * page 10, line 17 - line 30; claim - *; | [X]WO0151523 (BETH ISRAEL HOSPITAL [US], et al) [X] 1-3,6,7,10-12,16-19,23,24 * page 53, line 22 - line 31; claim - *; | [PX]WO0244328 (WAISMAN DAVID M [CA], et al) [PX] 1-4,6,7 * claim - *; | [DX] - SCAPPATICCI F A ET AL, "Statin-AE: a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity.", ANGIOGENESIS 2001, (2001), vol. 4, no. 4, ISSN 0969-6970, pages 263 - 268, XP002431004 [DX] 1,2,5-7,10-12,14,18,19,22-24 * Statin-AE Statin-AE-IRES-GFP * DOI: http://dx.doi.org/10.1023/A:1016067717433 | [X] - SAUTER B V ET AL, "Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, (20000425), vol. 97, no. 9, ISSN 0027-8424, pages 4802 - 4807, XP002145436 [X] 1-3,6,7 * GST-endostatin fusion protein. (cf. Materials and methods) * DOI: http://dx.doi.org/10.1073/pnas.090065597 | [DA] - HALIN C ET AL, "Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (200203), vol. 20, no. 3, ISSN 1087-0156, pages 264 - 269, XP002256784 DOI: http://dx.doi.org/10.1038/nbt0302-264 | [A] - NICULESCU-DUVAZ I ET AL, "RECENT DEVELOPMENTS IN GENE-DIRECTED ENZYME PRODRUG THERAPY (GDEPT) FOR CANCER", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON,, GB, (199908), vol. 1, no. 4, ISSN 1464-8431, pages 480 - 486, XP009057173 | [A] - AZAR Y ET AL, "GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells", APOPTOSIS, LONDON, GB, (200012), vol. 5, no. 6, ISSN 1360-8185, pages 531 - 542, XP002303415 DOI: http://dx.doi.org/10.1023/A:1009689529756 | International search | [Y]US6413513 (HOLADAY JOHN W [US], et al); | [Y]US6537554 (SHIMKETS RICHARD A [US], et al) | [X] - BOEHM ET AL., "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance", NATURE, (19971127), vol. 390, pages 404 - 407, XP000857413 DOI: http://dx.doi.org/10.1038/37126 | Examination | - FU OU-YANG ET AL, "Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, (20060101), vol. 66, no. 1, ISSN 0008-5472, pages 378 - 384, XP009106294 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-05-1578 | - Helfrich et al. (2000) J. Immunol. Methods 237, 131-145. | by applicant | WO9916889 | WO0011033 | US4797368 | US4879236 | WO0244328 | US5220007 | US6537554 | US4554101 | US4683202 | US5928906 | US2003228285 | US5925565 | US5935819 | US5871986 | US5670488 | US5641484 | US5139941 | US5284760 | - SAUTER ET AL., PNAS USA, (2000), vol. 97, pages 4802 - 4807 | - NICULESCU-DUVAZ ET AL., CURR OPIN MOL THER, (1999), vol. 1, pages 480 - 486 | - AZAR ET AL., APOPTOSIS, (2000), vol. 5, pages 531 - 542 | - HELFRICH ET AL., J IMMUNOL METHODS, (2000), vol. 237, pages 131 - 145 | - Remington's Pharmaceutical Sciences, MACK PRINTING COMPANY, (1990), pages 1289 - 1329 |